Use of Chronic Medications Among Patients with Non-Valvular Atrial Fibrillation

Paul T Kocis1, Guodong Liu2, Dinara Makenbaeva3

  • 1Anticoagulation Clinic, Penn State Health, Milton S. Hershey Medical Center, Hershey, PA USA.

Insights

Most non-valvular atrial fibrillation (NVAF) patients take multiple daily medications, making once-daily anticoagulant choice less critical for convenience. This highlights the complexity of managing NVAF patients with numerous prescriptions.

Area of Science:

  • Pharmacology
  • Cardiology
  • Health Services Research

Background:

  • Drug administration frequency influences treatment choices.
  • Non-valvular atrial fibrillation (NVAF) management involves complex medication regimens.

Purpose of the Study:

  • To characterize NVAF patients and their chronic medication use patterns.
  • To determine the proportion of NVAF patients taking non-anticoagulant medications more than once daily.

Main Methods:

  • Analysis of a national health insurance claims database (2008-2011).
  • Identification of NVAF patients and their prescription medication data.
  • Evaluation of comorbidities and stroke risk scores (CHADS2, CHA2DS2-VASc).

Main Results:

  • 324,172 NVAF patients included, with average CHADS2 (1.51) and CHA2DS2-VASc (3.08) scores.
  • 92.5% of patients used chronic medications, averaging 6.9 per patient.
  • 66.5% of all NVAF patients took medications more than once daily.

Conclusions:

  • Chronic non-anticoagulant medication use is prevalent in NVAF patients.
  • The majority of NVAF patients require multiple daily doses of non-anticoagulant medications.
  • Convenience of once-daily anticoagulants may be less impactful given overall medication complexity.
Abstract

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
591
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K